Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FBR-002 in Hospitalized COVID-19 Patients
NCT05279352Phase 2Unknown
- Sponsor
- Fabentech
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anti SARS-CoV-2 equine hyperimmune serum in coronavirus disease 2019 (COVID-19), sponsored by Fabentech. Status: unknown.
02
Drugs
anti SARS-CoV-2 equine hyperimmune serum
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05279352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279352.